| Part B: Supplementary Information Sheet (SIS) |
|
FR Recognition List Number
|
052
|
Date of Entry 07/15/2019
|
|
FR Recognition Number
|
8-517
|
| Standard | |
ISO 17327-1 First edition 2018-02
Non-active surgical implants - Implant coating - Part 1: General requirements |
|
Scope/AbstractThis document specifies general requirements for implant coatings, comprising both surface coatings and surface modifications, applied to non-active surgical implants. This document specifies requirements concerned with generic coating properties including chemical and phase compositions, surface texture, coating coverage integrity, dissolvability, coating thickness, adhesion strength, abrasion resistance, porosity and pore , and surface wettability.
This document is applicable to surface coatings, which are defined as layers of material with any different property than the natural surface of the substrate which are intentionally added to the substrate.
This document is applicable to surface modifications, which are defined as intentional conversion or reconstruction of the surface of the original substrate to form a new surface material consisting of components of the substrate's own material and possibly foreign material and forming a surface layer with different properties.
Since the pertinent properties of a coating and their needed level of characterization are highly dependent on the intended application of the implant, the generic nature of the general requirements in this document is not intended to either override or replace the provisions of application-specific performance standards.
This document is not applicable to surfaces modified by texturing with the exclusive intention to change the roughness of the surface or the strength of the raw material.
This document is not applicable to natively passivated metal surfaces. While this document is applicable to intentionally passivated metal surfaces, well-established materials passivated by conventional techniques, such as nitric acid immersion, are usually non-hazardous and can be described in a very basic manner.
This document is not applicable to implant coatings utilizing viable tissue.
This document is not applicable to laminates, i.e. composite materials made of multiple layers, e.g. vascular prosthesis constructed of different expanded polytetrafluoroethylene layers, except the exposed surface of the laminate, which can be an implant coating (see 3.1, note 2 to entry).
This document is not applicable to coverings, e.g. covered stents.
NOTE 1 This document does not contain requirements on biocompatibility. Nevertheless, this is a critical property of the device and coating and needs to be addressed during risk assessment.
NOTE 2 This document supplements applicable non-active surgical implant standards and ISO 14630.
NOTE 3 This document does not require that manufacturers have a quality management system in place. However, the application of a quality management system, such as that described in ISO 13485, could be appropriate to help ensure that the implant achieves its intended performance.
NOTE 4 Although fully porous implants are not coatings, some of the considerations in this document can also be applied to them.
|
|
| Extent of Recognition
|
Rationale for Recognition
| This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies. |
|
Relevant FDA Guidance and/or Supportive Publications*
Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement, Issued April,1994
510(k) Information Needed for Hydroxyapatite Coated Orthopedic Implants, Issued March 10, 1995 (revised February 20,1997)
Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements, Issued February 2000
Draft Guidance for Industry and Food and Drug Administration Staff: Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations, Issued June 2018, when final will represent the Agency's thinking on this topic
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
| FDA Technical Contacts
|
| Standards Development Organization
|
| FDA Specialty Task Group (STG)
|
| *These are provided as examples and others may be applicable. |
|
|
